-
Article
Towards a safe hospital: hepatitis C in-hospital micro-elimination program (HCV-HELP study)
Is hepatitis C virus (HCV) micro-elimination achievable at the hospital level with the structured strategies?
-
Article
Open AccessLower starting dose of afatinib for the treatment of metastatic lung adenocarcinoma harboring exon 21 and exon 19 mutations
Afatinib has shown favorable response rates (RRs) and longer progression free survival (PFS) in lung cancer patients harboring EGFR mutations compared with standard platinum-based chemotherapy. However, seriou...
-
Article
Open AccessIncreased risk of major depressive disorder in sleep apnea patients in Taiwan
The association between sleep apnea (SA) and depression had been reported in a few previous studies. However, whether SA increases the risk of major depressive disorder (MDD) has not been studied comprehensive...
-
Article
Bone-marrow-derived cell-released extracellular vesicle miR-92a regulates hepatic pre-metastatic niche in lung cancer
Metastatic tumors have been shown to establish a supportive pre-metastatic niche (PMN) in distant organs, which in turn determines disseminated tumor cells’ targeting of such organs. PMN is formed through the ...
-
Article
Open AccessThe clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations
Afatinib is a second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). Compared to cytotoxic chemotherapy, afatinib has been shown to have better efficacy in the treatment of ...
-
Article
Open AccessThe salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy
Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) such as gefitinib can provide better efficacy and prolonged progression free survival (PFS) than cytotoxic chemotherapy for metastatic lung ...
-
Article
Open AccessCorrection: Corrigendum: Cysteinyl Leukotriene Receptor Antagonists Decrease Cancer Risk in Asthma Patients
Scientific Reports 6: Article number: 23979; Published online: 07 April 2016; Updated: 12 May 2016 The Acknowledgements section in this Article is incomplete: “The authors thank the help from the Statistical A...
-
Article
Open AccessCysteinyl Leukotriene Receptor Antagonists Decrease Cancer Risk in Asthma Patients
Previous in vitro and in vivo studies have demonstrated the potential of using cysteinyl leukotriene receptor antagonists (LTRAs) for chemoprevention, but this has not been investigated in any clinical setting. W...
-
Article
Interactions between household air pollution and GWAS-identified lung cancer susceptibility markers in the Female Lung Cancer Consortium in Asia (FLCCA)
We previously carried out a multi-stage genome-wide association study (GWAS) on lung cancer among never smokers in the Female Lung Cancer Consortium in Asia (FLCCA) (6,609 cases, 7,457 controls) that identifie...
-
Article
Open AccessRisk factors for venous port migration in a single institute in Taiwan
An implantable port device provides an easily accessible central route for long-term chemotherapy. Venous catheter migration is one of the rare complications of venous port implantation. It can lead to side ef...
-
Article
Genome-wide association analysis identifies new lung cancer susceptibility loci in never-smoking women in Asia
Qing Lan and colleagues report the results of a genome-wide association study of lung cancer in never-smoking women from Asia. They identify three new susceptibility loci and confirm three other previously rep...
-
Article
Genetic variant in TP63 on locus 3q28 is associated with risk of lung adenocarcinoma among never-smoking females in Asia
A recent genome-wide association study (GWAS) of subjects from Japan and South Korea reported a novel association between the TP63 locus on chromosome 3q28 and risk of lung adenocarcinoma (p = 7.3 × 10−12); howev...
-
Article
Extreme thrombocytosis under the treatment by amoxicillin/clavulanate
Amoxicillin/Clavulanate related extreme thrombocytosis during the treatment of pneumonia has never been reported. We present a 54-year-old patient who was admitted due to pneumonia, and was treated with amoxic...
